Aquestive Therapeutics Inc [AQST] stock is trading at $2.85, up 10.89%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The AQST shares have gain 5.75% over the last week, with a monthly amount glided 20.25%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 21, February 2024, Aquestive Therapeutics to Report Fourth Quarter 2023 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET. In a post published today on Yahoo Finance, Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today announced that it will report results for the fourth quarter ended December 31, 2023 and provide an update on recent developments in its business after market close on Tuesday, March 5, 2024.
From an analyst’s perspective:
On January 03, 2019, Lake Street initiated with a Buy rating and assigned a price target of $14 on the stock. RBC Capital Mkts started tracking the stock assigning a Outperform rating and suggested a price target of $23 on August 20, 2018. JMP Securities initiated its recommendation with a Mkt Outperform and recommended $29 as its price target on August 20, 2018.
Aquestive Therapeutics Inc [AQST] stock has fluctuated between $0.72 and $2.95 over the past year. Aquestive Therapeutics Inc [NASDAQ: AQST] shares were valued at $2.85 at the most recent close of the market.
Analyzing the AQST fundamentals
Aquestive Therapeutics Inc [NASDAQ:AQST] reported sales of 48.06M for the trailing twelve months, which represents a growth of 13.43%. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.67 points at the first support level, and at 2.50 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.98, and for the 2nd resistance point, it is at 3.12.
Aquestive Therapeutics Inc [AQST] reported earnings per share of -$0.03 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.11/share, meaning a difference of $0.08 and a surprise factor of 72.70%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.1 per share as compared to estimates of -$0.12 per share, a difference of $0.02 representing a surprise of 16.70%.
Ratios To Look Out For
For context, Aquestive Therapeutics Inc’s Current Ratio is 1.76. Also, the Quick Ratio is 1.47, while the Cash Ratio stands at 0.05. Considering the valuation of this stock, the price to sales ratio is 3.96.
